Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | BURAN: buparlisib and paclitaxel in pre-treated HNSCC

Denis Soulieres • 18 Oct 2025
ESMO 2025
Head and Neck Cancer Buparlisib Paclitaxel
BURAN

Denis Soulieres, MD, Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses the Phase III BURAN study (NCT04338399) of buparlisib plus paclitaxel versus paclitaxel alone in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with PD-1/PD-L1 inhibitors. The addition of buparlisib did not improve overall survival or progression-free survival compared with paclitaxel alone, though a modest increase in response rate was observed. Safety findings were consistent with prior studies, with no new safety signals identified. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Denis Soulieres

Unmet needs in recurrent and metastatic head and neck cancer treatment
0:53
Unmet needs in recurrent and metastatic head and neck cancer treatment
Denis Soulieres • 18 Oct 2025
Predicting treatment outcomes in head and neck cancers with biomarkers
0:43
Predicting treatment outcomes in head and neck cancers with biomarkers
Denis Soulieres • 10 Sep 2022
The future role of immunotherapy in head and neck cancers
1:09
The future role of immunotherapy in head and neck cancers
Denis Soulieres • 10 Sep 2022

Related Videos

Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
1:04
Phase II study of FID-007 plus cetuximab in recurrent or metastatic HNSCC
Jacob Thomas • 31 May 2026
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
2:24
TARGET-HPV: neoadjuvant HPV16-targeted immunotherapy in oropharyngeal cancer
Ari Rosenberg • 31 May 2026
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
3:11
NRG-HN015: Phase II trial of perioperative systemic therapy in recurrent head and neck cancer
Nabil Saba • 1 Jun 2026
INO-3107 and B-cell immunity: implications for HPV-associated cancers
1:29
INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals